Open AccessRosiglitazone Prior Authorization Safety Policy: A Cohort Study
Author(s) -
Catherine I. Starner,
Beckie Fenrick,
John J. Coleman,
Peter Wickersham,
Patrick P. Gleason
Publication year - 2012
Publication title -
journal of managed care pharmacy
Language(s) - English
Resource type - Journals
eISSN - 1944-706X
pISSN - 1083-4087
DOI - 10.18553/jmcp.2012.18.3.225
Subject(s) - rosiglitazone , medicine , pharmacy , prior authorization , insulin , emergency medicine , family medicine , pharmacology
Prior authorizations (PA) are intended to promote safe and cost-effective medication use. Unwanted outcomes may occur, however, such as a patient forgoing drug therapy after a PA. The label for rosiglitazone was revised in November 2007 to include the warning of contraindicated use with nitrates or insulin, creating an opportunity for a PA directed at safe use.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom